|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500113249 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-26 11:41:47 |
|
注册时间: Date of Registration: |
2025-11-26 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
山东省消化道肿瘤队列研究 |
|
Public title: |
Study for gastrointestinal cancer cohort in Shandong Province |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
山东省消化道肿瘤队列研究 |
|
Scientific title: |
Study for gastrointestinal cancer cohort in Shandong Province |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
马恒敏 |
研究负责人: |
张楠 |
|
Applicant: |
Hengmin Ma |
Study leader: |
Nan Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 531 6762 6975 |
研究负责人电话: Study leader's telephone: |
+86 531 6762 6207 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
sd_mahengmin@163.com |
研究负责人电子邮件: Study leader's E-mail: |
nanzhang@vip.126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省济南市槐荫区济兖路440号 |
研究负责人通讯地址: |
山东省济南市槐荫区济兖路440号 |
|
Applicant address: |
No. 440, Jiyuan Road, Huaiyin District, Jinan City, Shandong Province |
Study leader's address: |
No. 440, Jiyuan Road, Huaiyin District, Jinan City, Shandong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
250117 |
研究负责人邮政编码: Study leader's postcode: |
250117 |
|
申请人所在单位: |
山东省癌症中心/山东第一医科大学附属肿瘤医院 |
||
|
Applicant's institution: |
Shandong Cancer Center, Cancer Hospital Afiliated to Shandong First Medical University |
||
|
研究负责人所在单位: |
山东省癌症中心/山东第一医科大学附属肿瘤医院 |
||
|
Affiliation of the Leader: |
Shandong Cancer Center, Cancer Hospital Afiliated to Shandong First Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SDTHEC2024003167 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东第一医科大学附属肿瘤医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Cancer Hospital Afiliated to Shandong First Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-03-28 00:00:00 |
||
|
伦理委员会联系人: |
李朝伟 |
||
|
Contact Name of the ethic committee: |
Chaowei Li |
||
|
伦理委员会联系地址: |
山东省济南市槐荫区济兖路440号 |
||
|
Contact Address of the ethic committee: |
No. 440, Jiyuan Road, Huaiyin District, Jinan City, Shandong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 531 6762 6929 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
山东第一医科大学附属肿瘤医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Cancer Hospital Afiliated to Shandong First Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省济南市槐荫区济兖路440号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 440, Jiyuan Road, Huaiyin District, Jinan City, Shandong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家重大公共卫生服务项目消化道癌筛查项目+自筹经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
The national major public health project-the Gastrointestinal Cancer Screening Program; self-collected funds |
||||||||||||||||||||||
|
Target disease: |
Gastrointestinal cancer |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
依托国家重大公共卫生专项—消化道肿瘤筛查项目、山东省癌症中心工作平台和各级医疗机构的临床资源,建设涵盖消化道肿瘤(食管癌、胃癌和结直肠癌)发生发展转归全过程人群的专病队列,以及与之对应的数据信息库和生物样本库,为开展消化道肿瘤疾病轨迹纵向研究提供支撑。 |
||||||||||||||||||||||
|
Objectives of Study: |
Building upon the national major public health project—the Gastrointestinal Cancer Screening Program—along with the Shandong Cancer Center's work platform and the clinical resources from medical institutions at various levels, the study aims to establish a specialized cohort that spans the entire process of gastrointestinal cancer development (including esophageal, gastric, and colorectal cancers). This will be complemented by creating a corresponding data repository and biological sample bank, which will support longitudinal studies on the disease trajectory of gastrointestinal cancer. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.消化道肿瘤高发区40-74岁居民; 2.自愿参加研究并签署知情同意书; 3.精神正常,具备民事行为能力。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Residents aged 40 to 74 in high-incidence areas of digestive tract tumors; 2. Voluntarily participate in the research and sign the informed consent form; 3. Mentally normal and capable of civil conduct. |
||||||||||||||||||||||
|
排除标准: |
1.明确诊断为消化道肿瘤或其他癌症的患者; 2.患有不能耐受内镜检查的严重疾病; 3.内镜检查禁忌症,如碘过敏。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with upper gastrointestinal cancer or other cancers 2. People with other serious illnesses that cannot tolerate endoscopy examination; 3. Contraindications for endoscopic screening (e.g. allergy to iodine solution or lidocaine). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-01-01 00:00:00至 To 2033-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-02-27 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,通过ResMan(www.medresman.org.cn)方式共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the end of the study, it was shared by ResMan (www.medresman.org.cn). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |